Prevalence of BRAFV600 in glioma and use of BRAF Inhibitors in patients with BRAFV600 mutation-positive glioma: systematic review is a research paper published in Neuro-Oncology (2022). On theSindex it has a DataRank of 0.621. It has been cited 62 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.621
From this paper's citation signal
Citation Network Contribution
0
Citation network not refreshed for this result
This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.
Learn more about DataRank methodology →Cancer Research UK
Grant: C30758/A29791
Cancer Research UK
Grant: C18281/A29019
Doctoral Research Fellowship
Grant: DRF-2018-11-ST2-048
National Institute for Health Research
Grant: NF-SI-0617-10145
Medical Research Council
Grant: G1100578
Medical Research Council
Grant: MR/N004272/1
Medical Research Council
Grant: G0701018
Medical Research Council
Grant: MR/M014533/1
Medical Research Council
Grant: MR/T044594/1
HCD: Synthesis of networks of evidence on test accuracy, with and without a 'gold standard'
Cancer Research UK
Grant: 29019
Cancer Research UK
Grant: S_4344
Bristol Biomedical Research Centre at University Hospitals Bristol
University of Bristol
Weston NHS Foundation Trust
Southmead Hospital Charitable Funds: Brain Tumour Bank
FWCI
3.72
Citation Percentile
1.0%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals